Q2 EPS Estimate for Tenax Therapeutics Decreased by Analyst

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Research analysts at William Blair decreased their Q2 2025 earnings per share (EPS) estimates for Tenax Therapeutics in a research report issued on Wednesday, May 14th. William Blair analyst M. Phipps now anticipates that the specialty pharmaceutical company will earn ($0.24) per share for the quarter, down from their prior forecast of ($0.22). William Blair has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. William Blair also issued estimates for Tenax Therapeutics’ Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.02) EPS, Q1 2026 earnings at ($0.26) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.05) EPS and FY2027 earnings at ($1.15) EPS.

TENX has been the topic of a number of other research reports. StockNews.com assumed coverage on shares of Tenax Therapeutics in a research report on Friday. They issued a “sell” rating on the stock. Leerink Partners set a $20.00 target price on Tenax Therapeutics in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Stock Up 3.3%

Shares of TENX stock opened at $5.89 on Monday. The company has a market cap of $24.43 million, a P/E ratio of -2.38 and a beta of 1.92. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $7.89. The business has a fifty day simple moving average of $5.86 and a 200 day simple moving average of $5.92.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings data on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20.

Institutional Investors Weigh In On Tenax Therapeutics

Several large investors have recently modified their holdings of TENX. Janus Henderson Group PLC acquired a new position in shares of Tenax Therapeutics in the 4th quarter valued at about $1,026,000. ADAR1 Capital Management LLC increased its holdings in shares of Tenax Therapeutics by 98.1% during the first quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock valued at $450,000 after acquiring an additional 34,048 shares in the last quarter. Millennium Management LLC bought a new position in shares of Tenax Therapeutics in the 4th quarter worth $166,000. Geode Capital Management LLC grew its position in Tenax Therapeutics by 32.4% in the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after purchasing an additional 5,964 shares during the period. Finally, Two Sigma Investments LP acquired a new position in shares of Tenax Therapeutics during the fourth quarter valued at about $84,000. 1.67% of the stock is currently owned by institutional investors and hedge funds.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.